Skip to main content

Table 5 Probabilsitic parameters

From: Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

Variable

Mean Value

Distribution (parameters)

95% C.I. based on parameters

IVIG Response Rate

0.473

beta (α = 35.52,β = 39.61)

(0.361, 0.585)

IVIG relapse rate (25 weeks)

0.13

beta (α = 4.03, β = 26.97)

(0.039, 0.266)

IVIG incremental utility

0.12

normal (μ = 0.12,β = 0.08)

(-0.05, 0.29)

Corticosteroid adverse events annual probailites

   

   Fracture

0.0098

beta (α = 1.20,β = 120.8)

(0.000,0.033)

   Diabetes mellitus

0.0043

beta (α = 0.48,β = 111.52)

(0.000,0.022)

   Cataract

0.0114

beta (α = 1.39,β = 120.61)

(0.001,0.036)

   Glaucoma

0.0008

beta (α = 0.09,β = 111.91)

(0.000,0.008)

   Serious Infection

0.0035

beta (α = 0.39,β = 120.8)

(0.000,0.020)

Glaucoma utility weight

0.96

beta (α = 214.32, β = 13.68)

(0.906,0.967)

Cataract utility weight-before surgery

0.62

beta (α = 62, β = 38)

(0.586,0.767)

Cataract utility weight post-surgery

0.90

beta (α = 90, β = 10)

(0.835,0.951)

Glaucoma utility weight

0.96

beta (α = 214.32, β = 13.68)

(0.906,0.967)